← Evidence map

ArticleAmerican journal of hematology2026

A Multicenter, Open-Label, Phase 2 Trial Comparing Crizanlizumab Combined With Standard Therapy to Standard Therapy Alone on Renal Function in Patients With Sickle Cell Nephropathy (STEADFAST).

Kenneth I Ataga et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

A Multicenter, Open-Label, Phase 2 Trial Comparing Crizanlizumab Combined With Standard Therapy to Standard Therapy Alone on Renal Function in Patients With Sickle Cell Nephropathy (STEADFAST). | OpenQuestion